Novartis’ prospects for launching a copy of GlaxoSmithKline’s Advair this year just went from highly unlikely to not happening.
Just a few hours after Allergan confirmed that it was in buyout talks for hot target Shire, it said it didn’t intend to make an offer.
Novartis investors' discontent with first-quarter results shows how much they're expecting of new CEO Vas Narasimhan.
Shire has already rebuffed Takeda three times, and now the Japanese drugmaker faces a competing bidder—Allergan.
Not even two months into a probe of officials accused of taking Novartis bribes, Greece's parliament is handing off the investigation.
The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.
AstraZeneca is looking to boost its key inhaler with two outcomes-based deals with regional insurers.
Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.
Jérôme Contamine, Sanofi's CFO for nearly a decade, plans to step down later this year after a transition period.
Ahead of what’s sure to be a big week for struggling Shire, a prominent investor group is rehashing complaints over the company’s executive pay policy.
